Home » Early Meridia Data May Indicate Higher Cardiovascular Risk
Early Meridia Data May Indicate Higher Cardiovascular Risk
Healthcare professionals should avoid prescribing
Abbott Laboratories’ anti-obesity drug Meridia for patients with a history of cardiovascular
events as preliminary data suggest patients taking the drug have a higher number of events including heart attack, stroke and death. According to preliminary
results of a six-year study, 11.4 percent of patients taking Meridia (sibutramine) experienced cardiovascular events compared with 10 percent of patients
taking a placebo, according to a recent FDA early communication.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May